9 completed, 3 unknown, 1 active not recruiting, 1 not yet recruiting. 17 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 9, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Unknown 1, Withdrawn 1 |
Follow Placebo Arm: new trials by email Literature Review of Placebo Arm trials Research Report on Placebo Arm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway Vericiguat 10 MG, Placebo, Insulin Sensitivity Test - Cardiovascular Diseases, Insulin Sensitivity/Resistance | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 200 | 2026-12-01 | 2026-01-23 |
| Low-dose IL-2 in Established T1D - The "PROREG" Study ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm - Diabetes Mellitus, Type 1, Diabetes | Phase 1 / Phase 2 | Withdrawn | Jay S. Skyler | 2023-06-01 | 2024-05-22 | |
| Rituximab in Patients With ST-elevation Myocardial Infarction Active arm 1000 mg, Placebo arm - ST Elevated Myocardial Infarction | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 372 | 2022-06-01 | 2026-11-10 |
| Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis IMU-838, Placebo matching IMU-838 - Multiple Sclerosis | Phase 2 | Unknown | Immunic AG | 450 | 2021-09-30 | 2024-04-29 |
| Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) Hydroxychloroquine Sulfate, Ascorbic Acid - COVID-19, Corona Virus Infection | Phase 2 / Phase 3 | Completed | University of Washington | 943 | 2020-03-31 | 2021-12-16 |
| This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3 - Chronic Spontaneous Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 311 | 2019-06-06 | 2022-04-29 |
| Preventing Asthma in High Risk Kids Omalizumab, Placebo - Asthma | Phase 2 | Active not recruiting | Boston Children's Hospital | 200 | 2018-11-27 | 2025-12-04 |
| A Study In Adults With Moderate To Severe Dermatomyositis PF-06823859 low, Placebo Arm, PF-06823859 high - Dermatomyositis | Phase 2 | Completed | Pfizer | 75 | 2018-01-23 | 2023-09-14 |
| Add-on Methotrexate for the Treatment of Schizophrenia Methotrexate, Placebo Arm - Schizophrenia | Phase 2 | Unknown | Sheba Medical Center | 100 | 2017-12-15 | 2017-12-12 |
| MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY BALM ARM, PLACEBO ARM - Dermatitis, Adverse Drug Reaction | Phase 1 / Phase 2 | Unknown | Basque Health Service | 86 | 2014-02-01 | 2016-08-02 |
| Trial of the Treatment of Chronic Laryngitis With Amitryptiline Amitriptyline, Placebo - Laryngeal Diseases, Chronic Laryngeal Neuropathy | Phase 2 / Phase 3 | Terminated | Boston Medical Center | 30 | 2013-09-01 | 2016-11-30 |
| Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo N-acetylcysteine, Placebo arm - Patients at Risk for Melanoma | Phase 2 | Completed | University of Utah | 100 | 2012-09-01 | 2017-07-31 |
| Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) gabapentin, placebo - Acute Lymphoblastic Leukemia, Neuropathy | Phase 2 | Completed | St. Jude Children's Research Hospital | 51 | 2012-01-24 | 2019-06-19 |
| A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma IPI-926, Placebo Arm - Conventional Chondrosarcoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 105 | 2011-02-01 | 2013-12-05 |
| Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis PUR 0110 Rectal Enema 250 mg, PUR 0110 Rectal Enema 500 mg, PUR 0110 Rectal Enema 1000 mg - Left-Sided Ulcerative Colitis, Proctosigmoiditis | Phase 2 | Completed | PurGenesis Technologies Inc. | 34 | 2010-06-01 | 2018-05-01 |
| Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm - Type 1 Diabetes Mellitus | Phase 2 | Completed | Yale University | 63 | 2006-09-01 | 2021-08-13 |
| Effect of an Extract of Green Tea on Adults With Type 2 Diabetes Extract of Green and Black Tea - Diabetes | Phase 2 / Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 48 | 2005-08-01 | 2023-10-13 |
Diabetes Mellitus (3) · Diabetes Mellitus, Type 1 (2) · Asthma (1) · Autoimmune Diseases (1) · Bone Neoplasms (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Chronic Urticaria (1) · Coronavirus Infections (1) · Dermatomyositis (1) · Drug Eruptions (1) · Insulin Resistance (1) · Laryngeal Diseases (1) · Lymphoma, Follicular (1) · Metabolic Diseases (1)
Assistance Publique - Hôpitaux de Paris (1) · Basque Health Service (1) · Boston Children's Hospital (1) · Boston Medical Center (1) · Dartmouth-Hitchcock Medical Center (1) · Immunic AG (1) · Infinity Pharmaceuticals, Inc. (1) · Jay S. Skyler (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · PurGenesis Technologies Inc. (1) · Sheba Medical Center (1) · St. Jude Children's Research Hospital (1) · University of Alabama at Birmingham (1) · University of Utah (1)
United States (13) · Germany (5) · Poland (4) · Canada (3) · France (3) · Netherlands (3) · Spain (3) · Czechia (2) · Hungary (2) · Russia (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1)
Alberto Pugliese, M.D. (1) · David A Baidal, M.D. (1) · Doralina Anghelescu, MD (1) · Douglas Grossman, MD, PhD (1) · J. Pieter Noordzij, MD (1) · Jay S Skyler, M.D. (1) · Jeffrey A Bluestone, PhD (1) · Kevan C Herold (1) · Pankaj Arora, MD, FAHA (1) · Patricia Seaone, MD (1) · Pedro Santabarbara, MD (1)
PMID 23086558, PMID 23423576, PMID 24115337, PMID 30954166, PMID 32493478, PMID 33242697, PMID 33284679, PMID 39798982, PMID 40986007, PMID 41874840, PMID 42273013, PMID 42542380
2009 (1), 2018 (1), R01DK057846 (1), U01AI179563 (1)